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Background: Daucus carota L.ssp.carota (wild carrot), an herb used in folk medicine worldwide, was recently
demonstrated to exhibit anticancer activity. In this study we examined the anticancer effect of Daucus carota oil
extract (DCOE) fractions on the human breast adenocarcinoma cell lines MDA-MB-231 and MCF-7 and clarified the
mechanism of action.
Methods and results: Using the WST assay, the pentane fraction (F1) and 1:1 pentane:diethyl ether fraction (F2)
were shown to possess the highest cytotoxicity against both cell lines. Flow cytometric analysis revealed that both
fractions induced the accumulation of cells in the sub-G1 phase, increase in apoptotic cell death and chromatin
condensation. The increase in apoptosis in response to treatment was also apparent in the increase in BAX and the
decrease in Bcl-2 levels as well as the proteolytic cleavage of both caspase-3 and PARP as revealed by Western blot.
Furthermore, treatment of MDA-MB-231 cells with either fraction significantly reduced the level of phosphorylated
Erk but did not show any effect on phosphorylated Akt. The combined treatment with a potent PI3K inhibitor
(wortmannin) and F1 or F2 fraction had a synergistic inhibitory effect on cell survival which shows that these two
drugs work on different pathways.
Conclusions: These results suggest that the pentane-based fractions of DCOE possess potential anti-cancer activity
that is mainly mediated through the Erk pathway.
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Breast cancer is one of the most common cancers among
women aged between 40–55 years, and is the leading
cause of death in women globally [1]. The present treat-
ment approaches, whether surgery, chemotherapy, im-
munotherapy or radiotherapy are usually accompanied
with adverse effects, leaving the patient weak and vulner-
able. Furthermore, acquired patient resistance to these
treatments poses a continuing problem that compro-
mises the effectiveness of anti-cancer therapy [2]. There-
fore, there is a growing interest in finding more effective
and selective anti-cancer remedies. The use of natural* Correspondence: mirvat.elsibai@lau.edu.lb
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est to researchers for the past few decades. In fact, over
25% of pharmaceutical drugs used in medicine today are
derived from plants [3]. For instance, plant secondary
metabolites such as terpenes, phenolics and alkaloids, are
extensively exploited in cancer research [4-9]. Currently,
there are four classes of plant-derived anticancer com-
pounds in clinical use: vinca alkaloids, epipodophyllotox-
ins, taxanes, and camptothecin derivatives [10].
Among the hallmarks of cancer cells are aberrant cell
cycle and apoptosis regulation. Cancer cells are known
to lose the ability to negatively regulate the cell cycle
leading to their continuous proliferation [11] and also
resist apoptosis even in the presence of apoptotic stimuli
[12]. Accordingly, a wide range of phytochemicals de-
rived from medicinal plants have been reported toal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cascades associated with cell cycle regulation and ap-
optosis. These cascades include mitogenic signaling
pathways, such as mitogen-activated protein kinases
(MAPKs) [13], PI3K-Akt pathway [14] and nuclear kappa
B pathway (NF-kB) [15]. These alterations induced by
phytochemicals are eventually correlated to the modula-
tion of cell cycle and/or apoptosis of cancer cells [16].
Wild carrot, Daucus carota L. ssp. carota, is a spiny–
fruited herb that grows in moderate regions throughout
the world. The Daucus carota oil extract from various
geographical locations constitutes mainly of monoter-
penes, sesquiterpenes, and phenylpropanoids [17,18].
Unlike the edible carrot, Daucus carota L. ssp. sativus,
few reports exist about the potential therapeutic use of
the wild carrot. In European folk medicine, it is used as
a urinary antiseptic and anti-inflammatory remedy for
cystitis and prostatitis [19]. The plant has also been
reported to possess antilithic, diuretic, [20,21] antibac-
terial, and antifungal activities [18,22,23]. Recent studies
conducted in our laboratories, showed that Daucus car-
ota oil extract (DCOE) exhibited anti-tumor [24,25],
antioxidant [24], anti-inflammatory, and anti-ulcer [26]
activities. The present study aims to evaluate the anti-
cancer activity of DCOE fractions against MDA-MB-231
and MCF-7 human breast cancer cell lines and to eluci-
date possible mechanisms of action.
Methods
Reagents
Dulbecco’s modified Eagle’s medium (DMEM) and di-
methyl sulfoxide (DMSO) were purchased from Sigma
(St. Louis, USA). The Annexin V/PI apoptosis detection
kit was purchased from Abcam (Cambridge, UK), and
WST-1 reagent was purchased from Roche (Mannheim,
Germany). All other chemicals used in this study were
purchased from Sigma (St. Louis, USA) unless otherwise
stated.
Sample collection and oil extraction
Daucus carota (Linnaeus) ssp. carota mature umbels
were collected at the post flowering season between May
and August from Byblos, Lebanon. The plant was identi-
fied according to the characteristics described in the
“Handbook of Medicinal Herbs” [21] and confirmed by
Dr. A. Houri, a Lebanese plant expert at the Lebanese
American University. A voucher specimen of the plant
material used in this study has been deposited in a pub-
licly available herbarium. The extraction procedure was
carried out according to the method described by Zeinab
et al. [25]. Briefly, umbels were air dried in the shade and
then cut into small pieces for oil extraction in methanol/
acetone (1:1) for 72 h. The extract was then filtered and
evaporated to dryness under reduced pressure. Theresidue was centrifuged and the oil was dried over anhyd-
rous sodium sulfate. The final yield (3.47%) was stored in
a closed amber bottle at 4°C until use.
DCOE fractionation
Thirty grams of DCOE were chromatographed on a sil-
ica gel column (35–70 mesh). The first fraction (F1) was
eluted with pentane (100%), the second fraction (F2)
with pentane: diethyl ether (50:50), the third fraction (F3)
with diethyl ether (100%) and the fourth fraction (F4)
with chloroform: methanol (93:7). Fractions were ana-
lyzed by TLC using hexane: ethyl acetate (70:30) as mo-
bile phase and plates were stained with 2% anisaldehyde.
Cell lines and culture
Human breast adenocarcinoma cell lines MDA-MB-
231 and MCF-7 were purchased from American Type
Culture Collection (ATCC, Rockville). Both cell lines
were cultured in a humidified incubator at 37°C and 5%
CO2 atmosphere in DMEM (Dulbecco’s modified Eagle’s
medium), supplemented with 10% fetal bovine serum
and 1% Penicillin-streptomycin.
Cell proliferation assay
The proliferation of the MDA-MB-231 and MCF-7 cells
was tested using WST-1 assay. Cells were plated in 96-
well plates at a concentration of 105 cell/ml for 24 h.
Both cell lines were then treated with increasing concen-
trations (10, 25, 50, and 100 μg/ml) of the four DCOE
fractions in DMSO for 48 h. At the end of the treatment
period, WST-1 reagent was added to the cells and incu-
bated in a humidified incubator at 37°C and 5% CO2
atmosphere for 3 h. The intensity of the produced for-
mazan was quantified at 450 nm using a microplate
ELISA reader. For wortmannin treatment, MDA-MB-
231 cells were incubated with or without wortmannin
(1 μM) for 1 h in a serum-free complete MEM prior
to treating cells with 25 and 50 μg/ml of F1 and F2
fractions for 48 h.
Apoptosis assay
The apoptotic effect of the most potent fractions F1 and
F2 of DCOE on MDA-MB-231 cells was determined by
Annexin V-FITC staining assay and measured by C6 flow
cytometer (BD Accuri Cytometers, Ann Arbor, MI USA).
The MDA-MB-231 cells (1 × 105 cells/ml) were treated
with different concentrations (25 and 50 μg/ml) of both
fractions and cultured in 6-well plates for 48 h. Treated
cells were harvested, washed with phosphate-buffer sa-
line (PBS) and then centrifuged at 500 g for 5 min. Then
cell pellet was suspended in 500 μL of Annexin V-FITC/
PI apoptosis detection kit at room temperature for 5 min
in the dark. Annexin V-FITC binding was analyzed by
flow cytometry (Ex = 488 nm; Em = 530 nm) FL1 channel
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for detecting PI staining. Annexin V-positive, PI-negative
cells were scored as early apoptotic, and double-stained
cells were considered as late apoptotic.
DAPI and annexin V staining
MDA-MB-231 cells were seeded on 25 mm square glass
cover slips. After treatment, cells were washed with PBS
and fixed with 3.7% paraformaldehyde for 10 min at
room temperature. Fixed cells were permeabilized with a
0.1% solution of Triton X-100 in PBS and then stained
by Annexin V conjugated to FITC or with 1 μg/ml of
DAPI solution for 20 min. The cells were washed with
PBS and observed with fluorescence microscope.
Cell cycle analysis
The effect of F1 and F2 fractions on cell cycle distribu-
tion was assessed by flow cytometry after staining the
MDA-MB-231 cells with propidium iodide (PI). Briefly,
the MDA-MB-231 cells (1 × 105 cells/ml) were treated
with different concentrations (25 and 50 μg/ml) of both
fractions for 48 h. The treated cells were harvested,
washed with PBS and fixed with 70% ethanol on ice.
Then cells washed with cold PBS, suspended in 200 μL
1X Propidium Iodide + RNase staining solution and in-
cubate at 37°C in the dark for 30 minutes. Propidium
Iodide Flow Cytometry Kit was used for cell cycle ana-
lysis. DNA content of the cells was measured by C6 flow
cytometer and the population of each phase was deter-
mined using CFlow Plus analysis software (BD Accuri
Cytometers, Ann Arbor, MI USA).
Western blot
MDA-MB-231 cells were treated with different concen-
trations of F1 and F2 (25 and 50 μg/ml) for 48 h. The
adherent and non-adherent MDA-MB-231 cells were
collected on ice, washed twice with PBS, lysed with lysis
buffer, and centrifuged at 12,000 g for 10 min at 4°C.
The cell lysate was heated at 100°C for 5 min, and the
protein content was determined by the Bio-Rad protein
assay (Bio-Rad, Hercules, CA, USA). The same amount
of proteins was loaded to a 10% SDS-PAGE. Proteins
were then transferred to PVDF membrane (Pall Corpor-
ation, Ann Arbor, USA) and blocked with 5% skim milk
for 2 h. The membranes were probed with primary anti-
bodies against Actin, p53, Bcl-2, Bax, Caspase-3, PARP,
Akt, p-Akt, Erk, and p-Erk (Abcam, Cambridge, USA)
at 4°C overnight. Later, the primary antibodies were
washed away with TBST for 1 h and the membranes
were treated with HRP-coupled secondary antibodies
(Promega Corp., Madison, USA) for 1 h, and washed with
TBST afterwards. Finally, Detection of each protein was
performed using the ECL kit (Abcam plc, 330 Cambridge
Science Park, Cambridge UK).Statistical analysis
Data was analyzed for statistical significance using one
way analysis of variance (ANOVA). Values of the differ-
ent tested parameters within each group are presented
as mean ± SEM. Significant main effect differences were
tested using Bonferroni post hoc test for multiple com-
parisons. All data were analyzed with the statistical pack-
age SPSS 18, and differences between groups were
considered statistically significant if p < 0.05.
All experimental protocols were approved by the Animal
Ethical Committee of the Lebanese American University,
which complies with the Guide for the Care and Use of
Laboratory Animals (Committee for the Update of the
Guide for the Care and Use of Laboratory Animals, 2010).
Results
MDA-MB-231 and MCF-7 breast cancer cells were
treated with different concentrations of fractions 1, 2, 3,
and 4 of DCOE for 48 h (Figure 1). The treatment with
the extract appeared to be dose-dependent with max-
imum inhibition of proliferation at higher concentrations
(50 and 100 μg/ml). MCF-7 cells showed the least re-
sponsiveness to the extract when compared to its more
malignant counterpart the MDA-MB-231 cell line. The
IC50 values of the four fractions at 48 h were 22, 32, 48,
and 43 μg/ml for MCF-7 and 17, 11, 27, and 23 μg/ml
for MDA-MB-231. The pentane fraction (F1) and pent-
ane/diethyl fraction (F2) showed the highest cytotoxicity
against both cell lines with the lowest IC50 (Additional
file 1: Table S1).
To determine whether growth inhibition by F1 and F2
on MDA-MB-231 human breast cancer cells was due to
cell cycle arrest or apoptosis, the cells were stained with
PI after permeabilization to look at the cell cycle profile
or with Annexin and PI to look for apoptosis. As shown
in Figure 2, treatment of MDA-MB-231 with F1 and F2
(25 and 50 μg/ml) for 48 h resulted in the increase of
cell percentage in the sub-G1 phase with hypodiploid
nuclei, indicating that both fractions could cause DNA
fragmentation. This increase was coupled with the de-
creased percentage of cells in the S and G2/M phases.
Figure 3 showed that cells treated with 25 μg/ml F1 or
F2 were in early apoptosis whereas cells treated with
50 μg/ml went into late apoptosis. To further confirm the
apoptotic effect of F1 and F2, control and treated MDA-
MB-231 cells were stained with DAPI and annexin.
Condensation of chromatin in nuclei was evident in cells
treated with either dose of F1 (Figure 4A). Besides,
annexin staining showed that both fractions induced the
phosphatidylserine (PS) translocation in the cell mem-
brane which is indicative of apoptosis followed by mem-
brane leakage (Figure 4B).
To explore the mechanism by which F1 and F2 in-
duced apoptosis, the expression levels of various pro-
Figure 1 Effect of DCOE fractions on cell proliferation. MDA-MB-231 and MCF-7 cells were treated with DCOE fractions (F1, F2, F3, and F4) at
concentrations of 10, 25, 50, and 100 μg/ml or with 0.5% DMSO for 48 h. Data are expressed as% survival of cells relative to control. Data are the
mean ± SEM from three independent experiments. *denotes P < 0.05 versus DMSO group as measured by one-way ANOVA.
Figure 2 Effect of F1 and F2 fractions on the cell cycle distribution in MDA-MB-231. (A) MDA-MB-231 cells were treated with 25 and 50
μg/ml of F1 or F2 fractions and control cells were treated with 0.5% DMSO for 48 hours, after which cells were stained with PI and analyzed for
DNA content by flow cytometry. The sub-G1 peak is considered as the apoptotic portion. The results shown are representative of 3 independent
experiments. (B) Bar graph shows the cell distributions of each phase of the cell cycle. Data are means ± SEM of three independent experiments.
*denotes P < 0.05 versus DMSO group as measured by one-way ANOVA.
Shebaby et al. BMC Complementary and Alternative Medicine 2014, 14:387 Page 4 of 9
http://www.biomedcentral.com/1472-6882/14/387
Figure 3 Apoptotic effect of F1 and F2 treatment on MDA-MB-231 cells. (A) Flow cytometric analysis of Annexin V-FITC and propidium
iodide (PI) quantifying the F1 and F2-induced apoptosis in MDA-MB-231. Dot plots of MDA-MB-231 cells treated with 0.5% DMSO, 25 or 50 μg/ml
of F1or F2 fractions for 48 hours. Viable cells are in the lower left (LL) region (negative for both annexin V-FITC and PI). Early apoptotic cells are
located in the lower right (LR) region (annexin V-FITC positive). Late apoptotic cells demonstrating extensive cellular and nuclear membrane
damage are located in the upper right (UR) region (double positive). Necrotic cells with destroyed cell membrane are in the upper left (UL) region
(PI positive). The results shown are representative of three independent experiments. (B) Bar graphs showing the percentages of cell population
of each quadrant in non-treated and treated MDA-MB-231 cells. Data are means ± SEM of three independent experiments.
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western blot. Treatment of MDA-MB-231 cells with F1
and F2 induced a decrease in the level of the inactive
caspase-3 in a dose dependent manner indicating its cleav-
age into activated form. In response to treatment, the level
of the 116-kDa PARP decreased and the level of theFigure 4 Apoptotic morphological changes of MDA-MB-231 cells follo
control (0.5% DMSO) and MDA-MB-231cells treated with 25 μg/ml of F1 or
examined by fluorescence microscopy. Arrows in A indicate apoptotic bodcleaved 85-kDa fragment increased (Figure 5A). Further-
more, the results of western blot indicated that the level of
the anti-apoptotic protein Bcl-2 was decreased, whereas
the pro-apoptotic protein BAX was increased. The ex-
pression of p53 protein was also assessed by western blot
and showed an increased level as shown in Figure 5A.wing treatment with fractions F1 or F2. Fluorescent micrographs of
F2 fractions for 48 hours and stained with DAPI (A) or annexin (B) and
ies of nuclear fragmentation. Scale bar is 10 μm.
Figure 5 Western blot analysis of apoptosis related proteins in MDA-MB-231 cells. (A) Effect of F1 and F2 fractions on the expression of
PARP, p53, caspase-3, Bcl-2, and Bcl2-associated X (BAX) proteins. Expression of β-actin was used as an internal control. MDA-MB-231 cells were
treated with 25 and 50 μg/ml of F1 or F2 fractions and control cells were treated with 0.5% DMSO for 48 hours. Western blots are representative
of three independent experiments. (B) The densitometer-intensity data of the proteins of each blot is presented as mean ± SEM from three
independent experiments. *denote P < 0.05 versus control (0.5% DMSO) as measured by one-way ANOVA.
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lysis to look for phosphorylated Akt. Upon treatment of
MDA-MB-231 with either fraction, no significant change
in phosphorylated Akt was observed as compared with
the control (Figure 6). On the other hand, the activity of
the MAPK pathway was assessed through examining the
level of phosphorylation of Erk. Results in Figure 6 re-
vealed a significant decrease in pErk upon treatment
with F1 or F2.
Since neither fraction acted through the PI3K pathway
in MDA-MB-231 cells, we investigated whether the com-
bined treatment of each fraction with wortmannin, aFigure 6 Western blot analysis of PI3K/Akt and MAPK/Erk pathways i
of Akt, p-Akt, Erk, p-Erk proteins in MDA-MB-231 cells. Cells were treated w
with 0.5% DMSO for 48 hours. Western blots were representative of three i
proteins of each blot is presented as mean ± SEM from three independent
measured by one-way ANOVA.selective PI3K inhibitor, would have a synergistic effect
on the inhibition of cell proliferation. WST results
showed a substantial decrease in cell survival of MDA-
MB-231 cells treated with 25 μg/ml of F1 or F2 along
with wortmannin (1 μM) compared to fraction alone
(Figure 7A and B).
Discussion
DCOE has been shown to have an antioxidant and anti-
cancer activities against breast and colon cancer cell
lines [24]. Previously, DCOE has been fractionated into
four major fractions and various constituents of eachn MDA-MB-231 cells. (A) Effect of F1 or F2 fractions on the expression
ith 25 and 50 μg/ml of F1 or F2-fractions and control cells treated
ndependent experiments. (B) The densitometer-intensity data of the
experiments. *denotes P < 0.05 versus control (0.5% DMSO) as
Figure 7 Effect of the combined treatment of F1 or F2 with wortmannin on MDA-MB-231 cells. (A) MDA-MB-231 cells were treated with 25
or 50 μg/ml of F1 or F2 or DMSO for 48 in the presence or absence of 1 μM wortmannin for 24 h. Cells were lysed and blotted for Akt and pAkt.
(B) Effect of F1 and F2 fractions on MDA-MB-231 cell survival at concentrations of 25 or 50 μg/ml for 48 hours in the presence or absence 1 μM
wortmannin. Inhibition of cell survival was assessed using the WST-1 assay. Data are expressed as% survival of cells. Data denote mean ± SEM from
three independent experiments. *denotes P < 0.05 versus control (0.5% DMSO) and **denotes P < 0.05 versus F1-25 or to F2-25 groups as
measured by one-way ANOVA.
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antioxidant activities were evaluated (Shebaby, et al.
2013, submitted). The present data demonstrated that
the DCOE fractions had significant anti-proliferative
effect against MDA-MB-231 and MCF-7 human breast
cancer cell lines. The DCOE fractions exhibited dose
dependent cytotoxicity against both cell lines. Moreover,
pentane (F1) and pentane/diethyl ether (F2) fractions
exhibited higher anticancer activity than the other
fractions (F3, F4).
This anticancer activity might be attributed to major
components present in the oil fractions. For example,
α-humulene and β-caryophyllene which are major com-
ponents of F1, have been reported to exhibit cytotoxic
activity against several human cell lines [27,28]. Simi-
larly, the sesquiterpene β-selinene and the phenylpro-
panoids, (E)-methylisoeugenol and elemicin, identified
in F2 fraction are also known to demonstrate anti-
proliferative activity and tumoricidial effects against
several human cell lines [8]. The anti-proliferative activ-
ity of the F2 fraction may be attributed to the presence
of the major compound which is tentatively identified
via GC-MS as 2-himachalene-6-ol. To the best of our
knowledge, this compound has not been reported in any
of the wild carrot species around the world and there
are no previous studies involving its anticancer activity.However, widdrol, a structural isomer of 2-himachalen-
6-ol, extracted from Juniperus chinensis, has been shown
to exhibit a potent anti-cancer activity against colon
adenocarcinoma cells HT29 by inhibiting their prolifera-
tion and inducing cell cycle G1 arrest [29]. In another
study, widdrol induced G1 arrest through the induction of
Chk2, p53 phosphorylation and CDK inhibitor p21 ex-
pression as well as inhibition of cyclin E, cyclin-dependent
kinase (CDK2) and retinoblastoma protein (pRB) [30].
Targeting the cell cycle and apoptotic pathways in can-
cer cells is an important approach for cancer treatment
and anti-cancer drug development [31]. Therefore, many
studies have been conducted to isolate and identify com-
pounds that induce cell cycle arrest and apoptosis [32].
In this study, we found that fractions F1 and F2 induced
apoptosis in MDA-MB-231 cells, as verified by the for-
mation of apoptotic nuclei that are characterized by
chromatin condensation and DNA fragmentation. These
results are consistent with an accumulation of cells in
the sub-G1 apoptotic phase. The cell cycle analysis also
revealed a decrease in cycling cells, which is indicative of
cell cycle arrest. The tumor suppressor p53 plays an im-
portant role in response to DNA damage or other gen-
omic instability. Functional p53 protein is crucial in
p53-dependent pathway leading to cell cycle arrest or
apoptosis [33]. MDA-MB-231 cells are known to harbor
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[34]. The increase in p53 protein following F1 or F2
treatment may not solely explain p53-dependent apop-
tosis. Therefore, the cell cycle arrest and apoptosis in
MDA-MB-231 cells is chiefly mediated through a p53-
independent mechanism.
To gain an understanding into the mechanisms con-
trolling apoptosis induced by F1 and F2, we examined
several components of the apoptotic pathways. The
proteins of the Bcl-2 family play an essential role in
apoptosis and are considered as a target for anticancer
therapy [35,36]. The Bcl-2 protein exhibits an anti-
apoptotic effect while BAX is a pro-apoptotic protein of
the Bcl-2 family [37,38]. Several studies indicated that
the ratio of Bcl-2 to BAX proteins decreases during
apoptosis [39]. In the present study, a decrease in the ex-
pression Bcl-2 and an increase in the expression of BAX
were observed after treating MDA-MB-231 cell lines
with F1 and F2. Additionally, activated caspase 3 plays a
crucial role in the final step of apoptosis and it is a key
protease for the cleavage of PARP resulting in the loss of
its enzymatic activity during apoptosis. This nuclear en-
zyme is involved in DNA repair and maintenance of
genomic integrity and it has been used as an important
marker of apoptosis [40]. The present data demonstrate
that cleavage of caspase 3 and PARP are evident after
treatment of MDA-MB-231 cells with F1 and F2 [41]
which is consistent with an increase in apoptosis.
The MAPK/ERK pathway plays an important role in
several cellular processes such as cell survival, cell prolif-
eration and apoptosis. It is reported that constitutively
activated ERK is responsible for high levels of cell
growth in various cancers [42,43]. On the other hand,
down-regulation of ERK activity is highly associated with
apoptosis [44]. In the present study, treatment of MDA-
MB-231 cells with either F1 or F2 significantly decreased
the phosphorylated ERK. Therefore, induction of apoptosis
in MDA-MB-231 cells after F1 or F2 treatment may be
mediated through the inhibition of the MAPK pathway.
The PI3K/AKT is another important intracellular
signaling pathway in regulating cell proliferation and
apoptosis. The serine/threonine protein kinase Akt is a
downstream molecule which is involved in the inactiva-
tion of several pro-apoptotic proteins and the activation
of anti-apoptotic proteins. The Akt pathway has an
essential role in regulating cell proliferation and survival
in cancer [45,46]. Our results revealed that apoptotic
concentrations of the F1 or F2 did not show any signifi-
cant effect on phosphorylated Akt compared to the con-
trol. However, a combined treatment with a potent PI3K
inhibitor (wortmannin) had a synergistic effect on apop-
tosis potentially through the inhibition of both MAPK
and PI3K pathways. This shows that wortmannin and
the fractions are acting distinct pathways.Conclusion
The present study demonstrates that the pentane fraction
(F1) and pentane/diehtylether fraction (F2) have potent
anticancer activity against MDA-MB-231 and MCF-7
human breast cancer cells. Both fractions inhibit cell
proliferation by inducing cell cycle arrest and apoptosis
in MDA-MB-231 cells. This induction of apoptosis is
through the inhibition of the ERK pathway. The results
suggest that the wild carrot could be considered a poten-
tial source for natural anticancer compounds. Future
work will focus on isolation and characterization of the
tentatively identified major compound and will explore
the prospective in vitro and in vivo anticancer capabilities.
Additional file
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